SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor

Leukemia Research

Volumn 38, Issue 4, 2014, Pages 496-502

  Sakamoto, Luis Henrique Toshihiro ^a,c   Andrade, Rosangela Vieira de ^b   Felipe, Maria Sueli Soares ^a,b   Motoyama, Andrea Barretto ^a   Pittella Silva, Fabio ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^c Brasília José Alencar Children's Hospital   (Brazil)

Author keywords

Acute lymphoblastic leukemia; Childhood; Gene expression; Lysine methyltransferase; Prognosis; SMYD2

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN; SMYD2 PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW; CANCER PROGNOSIS; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILDHOOD; GENE EXPRESSION; LYSINE METHYLTRANSFERASE; PROGNOSIS; SMYD2;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84897114159     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.01.013     Document Type: Article

References (42)

1. Pui C.H., Carroll W.L., Meshinchi S., Arceci R.J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. Journal of Clinical Oncology 2011, 29:551-565. official journal of the American Society of Clinical Oncology.
2. Stanulla M., Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Seminars in Hematology 2009, 46:52-63.
3. Greaves M. Childhood leukaemia. BMJ 2002, 324:283-287.
4. Vrooman L.M., Silverman L.B. Childhood acute lymphoblastic leukemia: update on prognostic factors. Current Opinion in Pediatrics 2009, 21:1-8.
5. Cheok M.H., Pottier N., Kager L., Evans W.E. Pharmacogenetics in acute lymphoblastic leukemia. Seminars in Hematology 2009, 46:39-51.
6. Davidsen M.L., Dalhoff K., Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 2008, 30:831-849.
7. Cunningham L., Aplenc R. Pharmacogenetics of acute lymphoblastic leukemia treatment response. Expert Opinion on Pharmacotherapy 2007, 8:2519-2531.
8. Fulbright J.M., Raman S., McClellan W.S., August K.J. Late effects of childhood leukemia therapy. Current Hematologic Malignancy Reports 2011, 6:195-205.
9. Ness K.K., Armenian S.H., Kadan-Lottick N., Gurney J.G. Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health. Expert Review of Hematology 2011, 4:185-197.
10. Lee-Sherick A.B., Linger R.M., Gore L., Keating A.K., Graham D.K. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. British Journal of Haematology 2010, 151:295-311.
11. Robison L.L. Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2011 2011, 238-242.
12. Moorman A.V. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Reviews 2012, 26:123-135.
13. Braoudaki M., Tzortzatou-Stathopoulou F. Clinical cytogenetics in pediatric acute leukemia: an update. Clinical Lymphoma, Myeloma and Leukemia 2012, 12:230-237.
14. Fuster J.L., Bermudez M., Galera A., Llinares M.E., Calle D., Ortuno F.J. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2007, 92:1723-1724.
15. Jones L.K., Saha V. Philadelphia positive acute lymphoblastic leukaemia of childhood. British Journal of Haematology 2005, 130:489-500.
16. Wong N.C., Ashley D., Chatterton Z., Parkinson-Bates M., Ng H.K., Halemba M.S., et al. A distinct DNA methylation signature defines pediatric pre-B cell acute lymphoblastic leukemia. Epigenetics 2012, 7:535-541. Official Journal of the DNA Methylation Society.
17. Dunwell T.L., Hesson L.B., Pavlova T., Zabarovska V., Kashuba V., Catchpoole D., et al. Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics 2009, 4:185-193. Official Journal of the DNA Methylation Society.
18. Greer E.L., Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nature Reviews Genetics 2012, 13:343-357.
19. Black J.C., Van Rechem C., Whetstine J.R. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Molecular Cell 2012, 48:491-507.
20. Yoshimi A., Kurokawa M. Key roles of histone methyltransferase and demethylase in leukemogenesis. Journal of Cellular Biochemistry 2011, 112:415-424.
21. Varier R.A., Timmers H.T. Histone lysine methylation and demethylation pathways in cancer. Biochimica et Biophysica Acta 2011, 1815:75-89.
22. Tsang D.P., Cheng A.S. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. Journal of Gastroenterology and Hepatology 2011, 26:19-27.
23. Dou Y., Hess J.L. Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia. International Journal of Hematology 2008, 87:10-18.
24. Eguchi M., Eguchi-Ishimae M., Greaves M. Molecular pathogenesis of MLL-associated leukemias. International Journal of Hematology 2005, 82:9-20.
25. Luciani M., Rana I., Pansini V., Caniglia M., Coletti V., Maraschini A., et al. Infant leukaemia: clinical, biological and therapeutic advances. Acta Paediatrica Supplement 2006, 95:47-51.
26. Hamamoto R., Furukawa Y., Morita M., Iimura Y., Silva F.P., Li M., et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nature Cell Biology 2004, 6:731-740.
27. Tan X., Rotllant J., Li H., De Deyne P., Du S.J. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:2713-2718.
28. Brown M.A., Sims R.J., Gottlieb P.D., Tucker P.W. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Molecular Cancer 2006, 5:26.
29. Hamamoto R., Silva F.P., Tsuge M., Nishidate T., Katagiri T., Nakamura Y., et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Science 2006, 97:113-118.
30. Silva F.P., Hamamoto R., Kunizaki M., Tsuge M., Nakamura Y., Furukawa Y. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells. Oncogene 2008, 27:2686-2692.
31. Cho H.S., Hayami S., Toyokawa G., Maejima K., Yamane Y., Suzuki T., et al. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 2012, 14:476-486.
32. Barros Filho M.C., Katayama M.L., Brentani H., Abreu A.P., Barbosa E.M., Oliveira C.T., et al. Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients. Brazilian Journal of Medical and Biological Research 2010, 43:1225-1231.
33. Abu-Farha M., Lanouette S., Elisma F., Tremblay V., Butson J., Figeys D., et al. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2. Journal of Molecular Cell Biology 2011, 3:301-308.
34. Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., Dorsey J.A., et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006, 444:629-632.
35. Wang L., Li L., Zhang H., Luo X., Dai J., Zhou S., et al. Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation. Journal of Biological Chemistry 2011, 286:38725-38737.
36. Brandalise S., Odone V., Pereira W., Andrea M., Zanichelli M., Aranega V. Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group. Leukemia 1993, 7(Suppl 2):S142-S145.
37. Stark B., Jeison M., Gobuzov R., Krug H., Glaser-Gabay L., Luria D., et al. Near haploid childhood acute lymphoblastic leukemia masked by hyperdiploid line: detection by fluorescence in situ hybridization. Cancer Genetics and Cytogenetics 2001, 128:108-113.
38. Kocak U., Gursel T., Kaya Z., Aral Y.Z., Albayrak M., Keskin E.Y., et al. ALL-BFM 95 treatment in Turkish children with acute lymphoblastic leukemia-experience of a single center. Pediatric Hematology and Oncology 2012, 29:130-140.
39. Kamps W.A., van der Pal-de Bruin K.M., Veerman A.J., Fiocco M., Bierings M., Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 2010, 24:309-319.
40. Schrappe M. Evolution of BFM trials for childhood ALL. Annals Hematology 2004, 83(Suppl 1):S121-S123.
41. Andersson A., Ritz C., Lindgren D., Eden P., Lassen C., Heldrup J., et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007, 21:1198-1203.
42. Komatsu S., Imoto I., Tsuda H., Kozaki K.I., Muramatsu T., Shimada Y., et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 2009, 30:1139-1146.